Collegium Acquires Tri-Nasal Nasal Spray for Allergic Rhinitis from Muro Pharmaceutical.Business Editors/Health/Medical Writers BIOWIRE2K CUMBERLAND, R.I.--(BUSINESS WIRE)--Oct. 7, 2003 Collegium col·le·gi·um n. pl. col·le·gi·a or col·le·gi·ums 1. An executive council or committee of equally empowered members, especially one supervising an industry, commissariat, or other organization in the Soviet Union. Pharmaceutical, Inc., a closely held A phrase used to describe the ownership, management, and operation of a corporation by a small group of people. In a closely held corporation, the same people often act as shareholders, directors, and officers, and no outside investors exist. specialty pharmaceutical company, today announced that it has acquired from Muro Pharmaceutical, Inc., all rights to Tri-Nasal(R) (triamcinolone acetonide triamcinolone acetonide (topical) (as´  tō´nīd),n brand names: , USP USP - unique sales point ) Nasal Spray, including the product's approved NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any and the right to market the product. This product expands Collegium's current portfolio of respiratory products that includes a patent pending formulation of anti-histamines. Muro received U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Tri-Nasal in 2000 as a once-daily, intranasal in·tra·na·sal adj. Within the nose. steroid medication for the treatment of seasonal and perennial allergic rhinitis in adults and children over age 12. The product was the subject of a Class III voluntary recall in 2002 for low potency in certain lots. Collegium expects to apply its expertise in chemistry, formulation, manufacturing and regulatory affairs to implement corrective measures and re-launch the product. A comprehensive development program is currently underway. The Company intends to pursue potential marketing partners for the product. Tri-Nasal competes in the $2 billion a year U.S. market for nasal inhaled steroids for the treatment of allergic rhinitis. Allergic rhinitis is the most common allergic condition and is increasing in prevalence. Estimates suggest that as many as 20-25% of the U.S. population are currently affected. The most common treatments include inhaled steroids and antihistamines Antihistamines Definition Antihistamines are drugs that block the action of histamine (a compound released in allergic inflammatory reactions) at the H1 . Competing products in these categories include Flonase(R) (Glaxo), Nasacort(R) (Aventis) and Rhinocort Aqua(R) (AstraZeneca). "Collegium is pleased to have acquired this important product from Muro. Allergic rhinitis is a large and growing market and inhaled corticosteroids remain a popular and effective treatment approach," said Jessica Wolfe, PhD, Vice President for Administration at Collegium. "We are well positioned to use our internal capabilities to address previous issues with this drug. With the approved NDA, we hope to have the product entering the U.S. as rapidly as possible." About Collegium Pharmaceutical, Inc. Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. The Company's products target market opportunities through product improvement and line extension strategies protected by intellectual property (IP), creating a portfolio of improved pharmaceutical products. Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering), marketing and clinical trials management to identify and execute product opportunities across multiple therapeutic areas. For more information, visit the Company's website at www.collegiumpharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion